18
2023-12
FDA granted a novel recombinant enzyme from Linno with “Orphan Drug Designation” (ODD) status for treatment of metachromatic leukodystrophy (MLD)
FDA granted a novel recombinant enzyme from Linno with “Orphan Drug Designation” (ODD) status for treatment of metachromatic leukodystrophy (MLD), a devastating inherited genetic disease that causes unmatured death of the affected pediatric patients.
16
2023-08
Linno was certified as 'Key Institution' by the Zhangjiang Science Park
Such designation symbolizes a recognition of Linno’s innovative breakthrough in BBB-penetration technology and the next-generation pathway-selective complement inhibitors. With this designation, Linno would be qualified for support of “Talent recruitment”
04
2022-11
Linno hosted R&D Day to celebrate its 3rd anniversary
In the afternoon of November 4, 2022, at the newly opened Zhangjiang Science Hall, a new landmark in Pudong, Shanghai, Linno Pharmaceuticals Inc. (Linno) hosted R&D day to celebrate its 3rd anniversary, with guest speakers and representatives from lea
18
2022-07
Linno completed Pre-A fundraising, focusing on enabling technology of blood-brain barrier penetration and the next-generation pathway-selective complement inhibitors
Linno Pharmaceuticals Inc. (Linno) today announced the completion of the Pre-A fundraising led by Puhua Capital and ZJ LEADING VC.
26
2021-04
Linno created a Scientific Advisory Board
Shanghai, April 26th, 2021. Linno Pharmaceuticals Inc. (Linno) today announced the establishment of a scientific advisory committee (SAB), and selected four top experts of their fields as its members.
25
2021-04
R&D Center Opened in Shanghai
Shanghai, April 25th, 2021. Linno (Shanghai) Pharmaceuticals Inc. (Linno) has officially moved into its newly renovated Shanghai R&D center. The new R&D center is located in the Zhangjiang Science and Technology Innovation Park ...